Olink Holding AB (publ)

stretching of business cycle type of issue more than anything else. We're not experiencing anything, you know, any losses, et cetera, in regard to that. So it's more of a timing type thing. So again, I think the overall trends in, you know, next generation proteomics and the demand there remains intact and just some timing things. And again, you know, the Europe comments are again off of extraordinarily strong comps from the year prior, you know, with the growth we had in Europe, especially in services, as Oscar had noted. So, you know, when the headwinds start to reside in biopharma, you know, we'll see. But, you know, again, we remain positive overall on that segment. And in the prior comments, we're not highly exposed to early biotech. So that's not a significant concern for us.

Okay. Thanks, Carl. And then just lastly, one technical question maybe for John. Could you guys just clarify the dynamic range of the Explorer offering with and without dilution? I think it's 8 to 10 logs is what your materials typically state. I think that assumes some level of dilution. If that's the case, would it be beneficial to increase the non-diluted dynamic range? Is there a path to do that in the future iteration of XOR?

Thanks, Kyle. Yeah, great to hear you pick up on the technical details. Yeah, so our approach is we've been very clear with most importantly to our customer, but also, of course, to investors, right? We try to be very particular in the acid development of each and every assay. So our approach is to ensure when we develop those assays that we have the appropriate relevant dynamic range to measure proteins in a healthy but also a severe disease state. So that sort of put the requirements on the dynamic range of the asset itself. And that's what we verify and validate in our asset development and product development efforts prior to releasing new products. So a quite unique approach in the very market and a very thorough, basically single-plex asset validation across each and every biomarker target. With that said, as I somewhat alluded to with molecular tricks. So, for example, capturing non-bound oligos to increase signal to noise, which will actually increase dynamic range and sensitivity. Are those things that we can do and are working on? Absolutely. Where is it most applicable for our product portfolio? So those are the type of sort of molecular designs that we are developing and contemplating and also where, you know, applying it to the products we think would make most sense for science. So hopefully that sort of in a broad perspective answers that question that yes, we definitely have capabilities and that we are, you know, led by science and customer needs and applying those efforts to produce a product.